Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a report released on Monday. They presently have a $83.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 29.79% from the stock’s previous close.
A number of other equities research analysts have also recently commented on the stock. Roth Capital initiated coverage on shares of Bluebird Bio in a research note on Thursday, September 22nd. They set a “buy” rating and a $87.00 target price on the stock. Goldman Sachs Group Inc. upgraded shares of Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price objective on the stock in a research report on Thursday, September 15th. Cantor Fitzgerald cut shares of Bluebird Bio from a “hold” rating to a “sell” rating and reduced their price objective for the company from $65.24 to $37.00 in a research report on Friday, October 14th. Leerink Swann lifted their price objective on shares of Bluebird Bio from $67.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday, October 14th. Finally, Maxim Group reiterated a “buy” rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $82.82.
Bluebird Bio (NASDAQ:BLUE) traded up 2.32% during midday trading on Monday, reaching $63.95. 505,529 shares of the company were exchanged. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $94.61. The company has a 50-day moving average of $56.23 and a 200 day moving average of $52.68. The firm’s market capitalization is $2.39 billion.
Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.82 million. During the same quarter in the previous year, the business posted ($1.18) EPS. Bluebird Bio’s revenue was up 17.4% on a year-over-year basis. Equities analysts predict that Bluebird Bio will post ($7.05) earnings per share for the current year.
In other news, insider Eric Sullivan sold 416 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total transaction of $27,872.00. Following the completion of the sale, the insider now directly owns 5,891 shares of the company’s stock, valued at $394,697. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.50% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Teachers Advisors Inc. raised its stake in shares of Bluebird Bio by 5.5% in the first quarter. Teachers Advisors Inc. now owns 46,048 shares of the company’s stock worth $1,957,000 after buying an additional 2,416 shares in the last quarter. BlackRock Inc. raised its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares in the last quarter. BlackRock Group LTD raised its stake in shares of Bluebird Bio by 11.2% in the first quarter. BlackRock Group LTD now owns 24,672 shares of the company’s stock worth $1,049,000 after buying an additional 2,493 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Bluebird Bio by 7.0% in the first quarter. JPMorgan Chase & Co. now owns 59,623 shares of the company’s stock worth $2,535,000 after buying an additional 3,906 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Bluebird Bio by 25.9% in the first quarter. State Street Corp now owns 1,201,936 shares of the company’s stock worth $51,088,000 after buying an additional 247,254 shares in the last quarter.
About Bluebird Bio